ArticleFrontiers in pharmacology2026

Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system.

Xiuping Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.